Safety and efficacy of Hemopran protective endorectal cream in the management of pregnancy-related haemorrhoidal disease: a single-center study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN71491809

Enrollment

140

Registered

2026-05-07

Start date

2025-02-11

Completion date

Unknown

Last updated

2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhoidal disease grade I–II in pregnant women Pregnancy and Childbirth

Interventions

All enrolled patients were treated with Hemopran® protective endorectal cream, a topical endorectal formulation indicated as a coadjuvant treatment for HD and anorectal mucosal irritation. Participant

Eligibility

Sex/Gender

Female

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Women aged =18 years with a confirmed pregnancy in any trimester 2. Clinical diagnosis of non-thrombosed grade I or II hemorrhoidal disease (HD) according to the Goligher classification

Exclusion criteria

Exclusion criteria: 1. Advanced HD requiring surgical intervention (grade III or IV) 2. The presence of concomitant anorectal conditions such as anal fissures or perianal abscesses 3. Known hypersensitivity to any component of the study product 4. The use of topical or systemic anti-hemorrhoidal treatments within 14 days prior to enrollment

Countries

Italy

Contacts

Public ContactDavide Carati

davide.carati@ekubergpharma.com+39 (0)3294513080

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 22, 2026